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Introduction
Pseudomonas aeruginosa is a ubiquitous gram- negative 
γ- proteobacterium which has been isolated from various 
sources, ranging from environmental samples (water, 
rhizosphere) to humans (Pirnay et al. 2009). In the 
human host, P. aeruginosa can cause disease in immu-
nocompromised as well as cystic fibrosis (CF) patients 
(Kerr and Snelling 2009; Lyczak et al. 2002). Although 
the environments from which P. aeruginosa strains can 
be retrieved are diverse, most of them, if not all, share 
the feature of harboring entire microbial communities 
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Abstract
S- type pyocins are bacteriocins produced by Pseudomonas aeruginosa isolates to 
antagonize or kill other strains of the same species. They have a modular 
 organization comprising a receptor- binding domain recognizing a surface con-
stituent of the target bacterium, a domain for translocation through the peri-
plasm, and a killing or toxic domain with DNase, tRNase, or pore- forming 
activity. Pyocins S2, S3, S4, and S5 recognize TonB- dependent ferri- siderophore 
receptors in the outer membrane. We here describe a new nuclease bacteriocin, 
pyocin S6, encoded in the genome of a P. aeruginosa cystic fibrosis (CF) clinical 
isolate, CF_PA39. Similarly to pyocins S1 and S2, the S6 toxin–immunity gene 
tandem was recruited to the genomic region encoding exotoxin A. The pyocin 
S6 receptor- binding and translocation domains are identical to those of pyocin 
S1, whereas the killing domain is similar to the 16S ribonuclease domain of 
Escherichia coli colicin E3. The cytotoxic activity was abolished in pyocin S6 
forms with a mutation in the colicin E3- equivalent catalytic motif. The CF_PA39 
S6 immunity gene displays a higher expression level than the gene encoding 
the killing protein, the latter being only detected when bacteria are grown under 
iron- limiting conditions. In the S1- pyocinogenic strain P. aeruginosa ATCC 25324 
and pyocin S2 producer P. aeruginosa PAO1, a remnant of the pyocin S6 killing 
domain and an intact S6- type immunity gene are located downstream of their 
respective pyocin operons. Strain PAO1 is insensitive for pyocin S6, and its 
S6- type immunity gene provides protection against pyocin S6 activity. Purified 
pyocin S6 inhibits one- fifth of 110 P. aeruginosa CF clinical isolates tested, 
showing clearer inhibition zones when the target cells are grown under iron 
limitation. In this panel, about half of the CF clinical isolates were found to 
host the S6 genes. The pyocin S6 locus is also present in the genome of some 
non- CF clinical isolates.
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(Kent and Triplett 2002; McGuigan and Callaghan 2015; 
Renwick et al. 2014). These communities are shaped by 
many symbiotic as well as antagonistic interactions. In 
order to compete with phylogenetically distant species, 
P. aeruginosa can produce several antagonistic molecules 
such as phenazines, pyoluteorin, and staphylolysin (LasA 
protease) among others (Gross and Loper 2009; Kessler 
et al. 1993). On the other hand, a particular P. aeruginosa 
strain also encounters other pseudomonads within the 
same niche. To compete with these closely related organ-
isms, P. aeruginosa is able to produce bacteriocins. These 
narrow- spectrum antibacterial proteins differ from tradi-
tional antibiotics, derived from secondary metabolism, in 
that they generally only affect members of related genera 
or even the same species. These toxins are generally pro-
duced under conditions of stress, such as nutrient deple-
tion or overcrowding (Riley and Gordon 1999; Riley and 
Wertz 2002a,b).
Bacteriocins produced by P. aeruginosa are called pyocins 
and several types of these bactericidal molecules have been 
described (Ghequire and De Mot 2014; Michel- Briand 
and Baysse 2002). R- and F- type pyocins are particles 
evolutionary related to bacteriophage tails, hence repre-
senting bactericidal tailocins (Ghequire and De Mot 2015; 
Ghequire et al. 2015). R- type pyocins are contractile but 
nonflexible, while the F- type pyocins are flexible but non-
contractile. Another large group of pyocins are the protease- 
sensitive “soluble” (S- type) pyocins. The S pyocins show 
a modular structure consisting of three domains: a receptor- 
binding domain (generally amino- terminal), a translocation 
domain, and a killing domain (carboxy- terminal) (Michel- 
Briand and Baysse 2002). Although recently several S- type 
pyocins encoding genes have been identified by screening 
draft and whole- genome sequences of P. aeruginosa strains 
(Ghequire and De Mot 2014), so far, only six different 
S- type pyocins have been functionally characterized, hav-
ing either DNase (S1, S2, S3, AP41) (Duport et al. 1995; 
Sano and Kageyama 1993; Sano et al. 1993; Seo and 
Galloway 1990), tRNAse (S4) (Elfarash et al. 2012) or 
pore- forming activity (S5) (Ling et al. 2010). A majority 
of S- type pyocins have been found to enter the bacterial 
cell via binding to a TonB- dependent outer membrane 
receptor involved in ferri- siderophore uptake. More spe-
cifically, pyocins S2 and S4 use the ferripyoverdine receptor 
FpvAI (Denayer et al. 2007; Elfarash et al. 2012), pyocin 
S3 targets FpvAII (Baysse et al. 1999), while pyocin S5 
recognizes the FptA ferripyochelin receptor (Elfarash et al. 
2014). Two other pyocin families, comparable in size to 
the S pyocins, are M- type and L- type pyocins. M- type 
pyocins host a module that cleaves lipid II peptidoglycan 
precursors (Barreteau et al. 2009). L- type pyocins host 
two monocot mannose- binding lectin domains, one of 
which is involved in binding the pseudomonad common 
polyantigen, and kill target cells via an unknown mecha-
nism (Ghequire et al. 2013, 2014; McCaughey et al. 2014).
Pyocins of the R- , F- , and S- types are produced when 
the cells are exposed to stress conditions, such as mito-
mycin treatment (Michel- Briand and Baysse 2002). The 
stress- induced SOS response activates the protease activity 
of RecA, resulting in the inactivation of the PrtR negative 
regulator of PrtN, the activator of pyocin genes expression 
(Matsui et al. 1993; Michel- Briand and Baysse 2002). 
Pyocin S5 represents an exception in the sense that its 
receptor- binding domain is centrally located and that it 
is not regulated by the PrtR–PrtN cascade (Ling et al. 
2010; Elfarash et al. 2014).
In this study, we identified a novel S- type pyocin in 
a CF epidemic P. aeruginosa strain, CF_PA39, isolated 
from a Belgian cystic fibrosis patient (Dingemans et al. 
2014). Pyocin S6 shares receptor- binding and translocation 
domains with the DNase pyocin S1, but has an rRNase 
cytotoxic domain similar to the E. coli bacteriocin colicin 
E3. The pyocin S6 toxin gene and cognate immunity gene 
are located adjacent to the conserved virulence gene toxA, 
in a genomic region where other S- type pyocins (S1, S2) 
have been integrated. The pyocin S6 locus is not only 
found in CF isolates, but is also present in few strains 
associated with other types of human infections.
Materials and Methods
Strains and plasmids
Bacterial strains and plasmids used in this study are 
 described in Table 1. Bacteria were grown at 37°C in 
Lysogenic broth (LB) medium (Life Technologies) or in 
iron- poor Casamino Acids (CAA) medium (Difco 
Laboratories). Liquid cultures were shaken in a New 
Brunswick Innova 4000 shaker at 200 rpm.
Structure modeling of the killing domain of 
pyocin S6
The I- TASSER server (http://zhanglab.ccmb.med.umich.
edu/I-TASSER/) (Yang et al. 2015) was used to acquire 
a predictive secondary structure of the rRNase domain 
of pyocin S6. Structure analysis and visualization were 
performed with PyMOL (www.pymol.org).
RNA isolation and semiquantitative reverse 
transcriptase (RT)- PCR
Using the RNeasy Mini kit (Qiagen), total RNA was iso-
lated from the clinical P. aeruginosa strains CF_PA17 and 
CF_PA39 after 24 h of growth in CAA medium (iron- 
limited growth condition) or LB medium (iron- sufficient 
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growth condition). Prior to reverse transcription, the RNA 
was treated with Turbo DNase (Ambion) via two 30- min 
incubation steps in the presence of 1 μL of (2 U/μL) 
Turbo DNase. The purity and concentration of the RNA 
were determined by gel electrophoresis using oprI primers 
(Table S1) (De Vos et al. 1997) and spectrophotometry 
(NanoDrop, Thermo Scientific). Next, cDNA was synthe-
sized starting from one microgram of Turbo DNase- treated 
(Ambion) total RNA using the iScript cDNA synthesis 
kit (Biorad). A negative control (no reverse transcriptase 
added) was included for each sample. RT- PCR was per-
formed on the cDNA templates using primers S6_Fw and 
S6_Rv, and S6I_Fw and S6I_Rv (Table S1). The PCR 
conditions included an initial denaturation of 5 min at 
95°C, followed by the first of 35 cycles: 45 sec denatura-
tion at 95°C, 45 sec annealing at 55°C, and 2 min exten-
sion at 72°C, followed by a final extension at 72°C for 
10 min. The PCR products were loaded onto an ethidium 
bromide- stained 2% agarose gel using TBE running buffer 
and visualized under UV light. A Smart Ladder MW- 
1700- 10B molecular weight marker (Eurogentec) was run 
to confirm the expected molecular weight of the ampli-
fication product.
Cloning of the pyocin S6 and S6 immunity 
genes
The pyocin S6 and adjacent immunity gene (1946 bp) 
were PCR- amplified from CF_PA39 genomic DNA using 
a KAPA HiFi PCR Kit. Primers are listed in Table S1. 
Amplified fragments were ligated into pET15b (+) (Merck, 
Germany) after NdeI/BamHI double digestion, and intro-
duced in DH5α competent cells. A colony PCR using 
the same primers was performed as selection step for 
colonies positive for the gene of interest. Plasmids from 
these positive colonies were purified using the PureYield 
Plasmid Miniprep system (Promega) and sequenced at 
the VIB Genetic Service Facility (Wilrijk, Belgium) using 
two sets of primers (external 715_S6_Fw and 716_S6_Rv, 
and internal 715_S6_Rv and 716_S6_Fw; Table S1), 
 ensuring complete coverage of the sequence. Pyocin S6 
genes, mutated in critical residues in the cytotoxic domain 
(D533A and E540A), were constructed via splicing by 
overlap extension (primers in Table S1) and introduced 
in pET15b (+).
Putative S6 immunity genes of P. aeruginosa strains 
CF_PA39 (350 bp) and PAO1 (370 bp) were PCR- amplified 
(primers in Table S1), SphI/BamHI double digested, ligated 
in shuttle vector pJB3Tc20, and introduced in DH5α. 
Sequence- verified plasmids were electroporated to indicator 
strain CF_PA109.
Overexpression and purification of the S6 
protein and S6 mutants
Firstly, the plasmid, of which the sequence was confirmed 
to contain the genes encoding pyocin S6 and the  immunity 
protein, was introduced into BL21(DE3)pLysS- competent 
cells using a heat- shock protocol. For overexpression, 
the bacteria with the recombinant plasmids were induced 
for expression of the cloned gene by growing them 
overnight at 28°C in the presence of 1 mmol/L IPTG 
after the OD600 reached 0.7. The harvested cells were 
resuspended in TGE buffer (50 mmol/L Tris- HCl (pH 
7.5), 10% glycerol, 1 mmol/L EDTA, and 10 mmol/L 
imidazole) and disrupted by French press treatment. The 
lysate was centrifuged at 10,000g for 15 min, and the 
clear supernatant was loaded onto a His- Trap FF column 
(Amersham Biosciences, GE Healthcare) integrated by 
AKTA TM FPLC system (Amersham Biosciences, GE 
Healthcare). The His- tagged proteins were eluted using 
elution buffer containing 500 mmol/L imidazole in TGE 
buffer (pH 7.5). The purity of the His- tagged proteins 
was confirmed after 12% SDS polyacrylamide gel elec-
trophoresis (SDS- PAGE, Invitrogen). The gels were 
stained with Coomassie Blue and a Kaleidoscope protein 
Table 1. Strains and vectors used in this study.
Strains or plasmids Features References
Pseudomonas aeruginosa
 PAO1 Wild- type P. aeruginosa (Stover et al. 2000)
 CF_PA1 to  CF_PA1251 CF clinical P. aeruginosa strains (Dingemans et al. 2014)
Escherichia coli
 DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1
(Hanahan 1985)
 BL21(DE3)pLysS E. coli B F– dcm ompT hsdS(rB
– mB
–) gal λ(DE3) [pLysS Camr] (Weiner et al. 1994)
Plasmids
 pET15b Expression vector, N- terminal his- tag, Apr (Studier et al. 1990)
 pJB3Tc20 Broad- host- range shuttle vector, Apr and Tcr (Blatny et al. 1997)
1With the exception of CF_PA8, CF_PA18, CF_PA21, CF_PA25, CF_PA29 to CF_PA33, CF_PA52 and CF_PA95 to CF_PA99. Camr and Apr indicate 
resistance to chloramphenicol and ampicillin, respectively
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ladder (BioRad) was used to confirm band size. The 
purified proteins were dialyzed against 2 L TGE buffer 
(pH 7.5). The protein concentration was determined 
using a NanoDrop 1000 spectrophotometer (Thermo 
Scientific). The pooled pure proteins were divided into 
small aliquots and stored at −20°C, which were frozen 
and thawed individually before each manipulation. A 
similar expression and purification  procedure was fol-
lowed up for the expression and  purification of pyocin 
S6 mutants (D533A and E540A).
Pyocin sensitivity assay
In order to verify the sensitivity of different clinical isolates 
(Table 1) to purified pyocin S6, a pyocin spotting assay 
was performed. This involved spotting 10 μL of the puri-
fied pyocin protein (10 mg/mL) onto CAA and LB plates 
with a bacterial cell layer containing 5 × 106 cells/mL 
and incubated at 37°C for 24 h. Strains were classified 
as sensitive if a growth- inhibitory zone appeared on and/
or around the spotting site, and resistant if no such 
 inhibition zone was apparent.
A minimum inhibitory concentration (MIC) test was 
done in triplicate by spotting a twofold serial dilution 
(starting concentration, 17 mg/mL) of pyocin S6 onto a 
lawn of the sensitive P. aeruginosa strain CF_PA109 
(5 × 106 cells/mL), which was grown overnight on a 
CAA plate at 37°C for 24 h.
Screening of clinical strains for the presence 
of pyocin S6
Chromosomal DNA from our collection of 110 P. aer-
uginosa CF strains (Dingemans et al. 2014) was prepared 
using the DNeasy Blood and Tissue Kit (Qiagen) and 
screened for the gene encoding the S6 pyocin using prim-
ers S6_Fw and S6_Rv (Table S1). The PCR conditions 
included an initial denaturation of 5 min at 95°C, fol-
lowed by the first of 30 cycles: 45 sec denaturation at 
95°C, 45 sec annealing at 60°C, and 1 min extension at 
72°C, followed by a final extension at 72°C for 10 min.
Results
Nucleotide and amino acid sequences of 
pyocin S6
The genome sequence of P. aeruginosa CF_PA39, an isolate 
belonging to a Belgian epidemic P. aeruginosa CF clone 
(Dingemans et al. 2014), was screened for the presence 
of existing S- type pyocin genes. Strikingly, although a 
coding region corresponding to the receptor- binding (RBD) 
and translocation domains (TD) of pyocin S1 (Table 2) 
was detected in the genome of P. aeruginosa CF_PA39, 
the ORF sequence diverged at the encoded carboxy- terminal 
domain, sharing 49.4% amino acid identity and 69% 
similarity with the rRNase killing domain (KD; Pfam 
PF09000) of colicin E3 (Table 2). Furthermore, a second 
ORF overlapping with the putative novel pyocin gene was 
identified. Considering its genetic organization (ATG start 
codon overlapping with TGA stop codon of upstream 
gene) and small size (<100 amino acids), this ORF likely 
encodes an associated immunity protein, albeit showing 
only borderline sequence similarity to the colicin E3 
 immunity protein (85 residues; 18.5 % identity, 37% 
similarity).
Remarkably, the position of the ORFs encoding the 
putative novel S- type pyocin (designated S6) and its 
 immunity gene corresponds to the equivalent loci encod-
ing pyocin S1 or pyocin S2 (Fig. 1). In this region between 
the well- conserved genes toxA and PA1153 (PAO1 
 annotation), yet another S- type pyocin gene pair is found, 
predicted to encode putative pyocin S7 (Ghequire and 
De Mot 2014; Fig. 1). The latter apparently combines 
the RBD of pyocin S2 with the TD and KD of pyocin 
S6 (Table 2). Downstream of its pyocin S2 locus, P. aer-
uginosa PAO1 harbors a S6- type immunity gene (previously 
described as colicin E3 immunity; Denayer et al. 2007), 
preceded by a 3’- remnant of the pyocin S6 toxin gene 
(250 nucleotides), suggesting that the latter was deleted 
while the putative immunity gene remained intact. A 
second orphan gene encoding an immunity protein, car-
rying domain PF09204 and typically associated with a 
Table 2. Comparison of pyocin S6 with other pyocins and colicin E3. 
Domain/protein Length (AA) Pyocin S1 (618 AA) Pyocin S2 (689 AA) Pyocin S7 (642 AA) Colicin E3 (551 AA)
Amino- terminal 343 99.7 34.7 34.7 NA
Pyocin_S (PF06958) 146 95.8 95.8 99.3 NA
rRNase (PF09000) 82 NA NA 100 49.4
Immunity1 77 NA NA 100 18.5
The amino acid identity (%) between toxin domains and between cognate immunity proteins is shown. The Pfam domains present in pyocin S6 toxin 
(571 AA) are specified. NA, not applicable (toxin–immunity pairs of a different type).
1Identity to rRNase immunity orphans (77 AA) in other strains: ATCC 25324 and DK2 (85.7%); PAO1 (84.4%).
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tRNase such as colicin D, is located downstream of PAO1 
PA1152. Both orphan immunity genes are also located 
between the PA1152- PA1153 homologues in the equivalent 
genomic region of the S1- pyocinogenic strain ATCC 25324 
and in strain DK2. The latter, however, has only retained 
the DNase immunity gene without a corresponding  nuclease 
gene.
The nucleotide sequence of the two ORFs in the  genome 
of P. aeruginosa CF_PA39 spans a region of 1946 
 nucleotides (Fig. S1). The first ORF encodes a protein 
of 571 amino acids (pyocin S6) while the second ORF 
(putative immunity protein of pyocin S6) specifies a 
small protein of 77 amino acids. The predicted molecular 
weights of these proteins are 60,901 and 8586 Da, 
 respectively (Fig. S1). The structural domain organization 
of pyocin S6 was found to be the same as discovered 
for pyocin S1, with an amino- terminal polypeptide of 
241 amino acids, corresponding to the RBD, a central 
TD (245 amino acids) and a carboxy- terminal KD (85 
amino acids). As found by Sano et al. (Sano et al. 1993) 
for pyocin S1, a regulatory P- box is present 74 nucleo-
tides upstream of the start codon (Fig. S1). The P- box 
is located 60–100 bp upstream of the Shine–Dalgarno 
sequence of the toxin gene and serves as a binding site 
for the PrtN protein, which positively regulates pyocin 
expression (Ghequire and De Mot 2014; Matsui et al. 
1993). The sequence is usually composed of four repeats 
of 10–11 nucleotides and each repeat has a consensus 
sequence of ATTGnn(n)GTnn(n) (Sano et al. 1993). 
Similar to other characterized S- type pyocins, a putative 
ribosome binding site of the immunity gene was found 
in the region encoding the C- terminal portion of the 
toxin protein, located eight bases upstream of the 
methionine- encoding start codon. An inverted repeat of 
eight nucleotides, separated by eight nucleotides, was 
found downstream of the second ORF, which could serve 
as a transcription terminator by forming a stem- loop 
structure (Fig. S1).
A 3D model of the KD of pyocin S6 was generated 
using the I- TASSER server (Fig. 2A). Structural similarity 
with the KD of colicin E3, for which a crystal structure 
has been solved, can be observed (Fig. 2B) (Soelaiman 
et al. 2001). In colicin E3, D510, H513, and E517 are 
essential residues for bacteriocin activity, whereas a 
 significant reduction in activity was observed when R495, 
R497, E515, and R545 are mutated (Walker et al. 2004). 
Interestingly, in pyocin S6, these residues are perfectly 
conserved (Fig. 2C). Moreover, the orientation of the side 
chains, expected to contribute to the rRNase activity (D533, 
H536 and E540, respectively), is highly similar.
Expression of pyocin S6 and its immunity 
gene
In order to test whether the genes encoding the pyocin 
S6 and its immunity protein are expressed, we used two dif-
ferent media, LB (iron sufficient) and CAA (iron  limited), 
and a semiquantitative reverse transcription- polymerase 
Figure 1. Genetic organization of the pyocin S6 locus in the genome of P. aeruginosa CF_PA39. Comparison between the pyocin S6 locus in 
P. aeruginosa CF_PA39 with the loci encoding pyocin S1 (P. aeruginosa ATCC 25324), pyocin S2 (P. aeruginosa PAO1), and putative pyocin S7 
(P. aeruginosa BWH057). The equivalent immunity- encoding genomic region of P. aeruginosa DK2 lacking a pyocin toxin gene is included. Synteny is 
visualized by sequence conservation (light gray shading) for the genes (represented by arrows) located between the orthologs of toxA (PA1148) and 
PAA1153 of P. aeruginosa PAO1 (nonannotated ORFs marked with an asterisk). The color code specifies the type of encoded nuclease and cognate 
or orphan immunity protein (Imm). Conserved receptor- binding domains (RBD) are highlighted in the same color. Darker gray shading delineates the 
region encoding the translocation domain, conserved across the four pyocins. Dotted lines indicates the lack of an equivalent sequence. The same 
pyocin S6 gene context is found in P. aeruginosa strains AZPAE14840 and AZPAE14899. In several other S6 pyocinogenic strains the unknown gene 
upstream of CF_PA39 toxA, absent from strain PAO1, is equally lacking (AZPAE14862, AZPAE14931, AZPAE14934, AZPAE14937, AZPAE14951, 
AZPAE14976, 130_PAER, PA45) (Table S2). The P. aeruginosa PA45 locus further differs by the absence of the unknown gene downstream of the 
CF_PA39 PA1153 homologue.
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chain reaction (RT- PCR) was performed (Fig. 3). To 
 determine the relative abundance of expressed genes, prim-
ers specific for the housekeeping gene oprI were used, 
using genomic DNA from P. aeruginosa CF_PA39 as a 
positive control. The test was performed on two strains, 
CF_PA17 and CF_PA39, belonging to the same clone but 
isolated from different CF patients, both grown overnight 
in LB or CAA medium.
The obtained results show that signal intensities with 
regard to the housekeeping oprI gene were similar, 
indicating comparable mRNA levels (Fig. 3). Further, 
it was found that the expression of the pyocin S6 gene 
is very low, though slightly increased when the cells 
were grown in the iron- limited CAA medium. Strikingly, 
the expression of the immunity gene was much higher 
and it could be detected under both growth conditions, 
suggesting, either an uncoupling between the transcrip-
tion of the two genes, despite their operon- like organi-
zation or a different stability of the pyS6 and imm6 
transcripts.
Figure 2. Structural similarity of the killing domains of pyocin S6 and colicin E3. (A). 3D model of the KD of pyocin S6 (B). Cartoon representation of 
the rRNase KD of colicin E3. Side chains of conserved residues contributing to the activity in colicin E3 (B), and corresponding residues in pyocin S6 
(A) are shown as sticks. Amino- and carboxy- termini of the KDs are marked with N and C, respectively. (C). Sequence alignment of the KDs of PyS6 
and ColE3. Gray shading reflects the degree of conservation. Residues involved in toxic activity of ColE3, and the corresponding residues in PyS6 are 
boxed in red. PyS6 residues that were mutated to alanine in this study are marked with an asterisk.
Figure 3. Effect of iron limitation on the expression of pys6 and imm6. Using semiquantitative reverse transcriptase (RT) RT- PCR, the expression of 
pys6 (884 bp) and oprI (248 bp) (A) and imm6 (127 bp) and oprI (248 bp) (B) was determined for P. aeruginosa CF_PA17 and P. aeruginosa CF_PA39 
grown in LB or casamino acids (CAA). +RT and −RT indicate that reverse transcriptase was added or not, respectively. Fifty nanograms of genomic 
DNA isolated from P. aeruginosa CF_PA39 was included as a positive control (lanes marked with a “+”). The molecular weight size marker is shown 
in the lanes marked with an “L”. The lower bands observed in the - RT reactions represent primer dimers and are not observed in the +RT reactions. 
pys6, pyocin S6 gene. imm6, pyocin S6 immunity gene.
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Cloning, overexpression, and purification of 
pyocin S6
The DNA sequence encoding both pyocin S6 and its 
 putative immunity protein (1946 bp) was cloned into a 
pET15b vector. Plasmid pET15b provides an inducible 
promoter (Plac) for cloned genes and allowed expression 
of the P. aeruginosa DNA in E. coli BL21 (DE3) pLysS. 
At an OD600 nm of 0.7 and after 1.5 h of further growth, 
samples were taken of the E. coli culture before and after 
IPTG induction, respectively, to test for basal expression 
of the cloned fragment. Subsequently, the samples were 
analyzed by 12% SDS PAGE. A clear band below 70 kDa 
(with 63 kDa as expected size of the His- tagged pyocin 
S6 protein) was only observed for the induced culture, 
indicating that the cloned fragment was expressed under 
control of Plac and not under its native promoter. The 
purified protein appeared as a single band after 12% SDS 
PAGE (Fig. S2A). The small immunity protein could only 
be detected when the gel was overloaded (data not shown).
Pyocin S6 activity
To verify the activity of the purified protein, a sensitivity 
assay was performed where pyocin S6 was spotted on 
bacterial lawns of 110 P. aeruginosa CF isolates with known 
ferri- pyoverdine receptor types (Elfarash et al. 2014), grown 
on both LB and CAA. Pyocin S6 was found to be active 
against a total of 22 strains (20%) (Table 3), confirmed 
by either clear punched- out zones of no growth or thin-
ning of growth around the spotting area. However, sus-
ceptibility was more pronounced under iron limitation, 
as growth- inhibitory effects were only clearly visible for 
strains grown on CAA plates (Fig 4A and B). As the 
ferri- pyoverdine receptor types were previously determined 
for the 110 strains by multiplex PCR (Dingemans et al. 
2014), we tried to establish a relationship between the 
killing activity of pyocin S6 and the presence of a specific 
ferri- pyoverdine receptor. However, the results presented 
in Table 3 do not show any clear correlation, suggesting 
pyocin S6 does not target a specific ferri- pyoverdine 
 receptor type.
To exclude the possibility that the purified pyocin 
 activity could be contaminated by bacteriophages and to 
establish a MIC, a twofold serial dilution (starting 
concentration, 17 mg mL−1) of pyocin S6 was titrated 
against the sensitive indicator strain CF_PA109 (Fig. 4C). 
If any inhibitory activity is due to the presence of bac-
teriophage, the more diluted fractions will produce 
 individual plaques of phage lysis. If inhibition zones ap-
pear without plaque formation, it is assumed that only 
pyocin activity is present (Osman 1965). No bacteriophage 
activity was found and the MIC was determined to be 
260 μg mL−1.
Furthermore, based on the predicted 3D model (Fig. 2), 
we constructed two mutants in the conserved residues 
expected to be critical for the rRNase activity in the KD 
domain of pyocin S6. D533 and E540 in pyocin S6, cor-
responding to D510 and E517 in colicin E3 (Fig. 2C), 
respectively, were mutated to alanine. The mutant pyocins 
were expressed in BL21(DE3)pLysS and purified (Fig. S2A), 
and spotted onto CF_PA39. As expected, pyocin activity 
was lost (Fig. S2B).
Pyocin S6- downstream gene provides 
immunity
The putative pyocin S6 immunity gene, accompanied by 
its cognate ribosome- binding site, was cloned in shuttle 
vector pJB3Tc20, and introduced in pyocin S6- susceptible 
strain CF_PA109 via electroporation. After spotting pyocin 
S6 onto a lawn of cells carrying this plasmid, no halo 
could be observed, whereas CF_PA109 carrying pJB3Tc20 
empty vector remained susceptible. This confirms that 
the pyocin S6- downstream gene indeed acts as a cognate 
immunity gene (Fig. S2C and D).
Next, the putative pyocin S6 immunity gene of strain 
PAO1 was cloned in shuttle vector pJB3Tc20. The encoded 
PAO1 protein shares 84.4% amino acid identity with the 
pyocin S6 immunity protein from CF_PA39 (65 identical 
sites on 77 residues). The upstream DNA region in strain 
PAO1 is almost identical to CF_PA39, only differing by 
one nucleotide. The resulting plasmid was electroporated 
to CF_PA109 and equally tested for pyocin S6 susceptibil-
ity. No inhibitory activity could be observed (Fig. S2E), 
indicating that this rRNase immunity protein provides 
protection against pyocin S6 as well. Strain PAO1 in 
 insensitive to pyocin S6 activity (data not shown), which 
is in support of the demonstrated S6 immunity 
activity.
Table 3. Phenotypes of sensitivity or resistance to pyocin S6 of 110 P. aeruginosa CF isolates previously checked for the type of FpvA receptor gene 
by multiplex PCR.
FpvAI FpvAI + FpvB FpvAIIb FpvAIIb + FpvB FpvAIII FpvAIII + FpvB
S6 Resistant 0 23 20 16 0 29
S6 Sensitive 2 11 0 7 1 1
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Screening of clinical strains for the presence 
of pyocin S6
PCR analysis was performed to determine the frequency 
of occurrence of the pyocin S6 gene in the clinical isolates 
investigated in this study. Fifty- six of the 110 (51%) strains 
from the UZ Brussel CF clinic proved to be positive for 
the gene, explaining in part the relatively low percentage 
(20%) of susceptible strains. The pyocin S6- positive cells 
should be immune due to the constitutive expression of 
the immunity gene (Fig. 3), providing protection against 
the exogenous killing protein.
Discussion
In a recent review, Ghequire and De Mot (2014) presented 
the result of a screening of different P. aeruginosa genomes 
for the presence of tailocins (R- and F- pyocins) and S- 
type pyocins, revealing the presence of uncharacterized 
S- type pyocin genes. In this study, we present the func-
tional characterization of such a bacteriocin, pyocin S6, 
the gene of which was detected in the genome of a CF 
epidemic strain of P. aeruginosa. A comparison with the 
genomic organization of the pyocin S2 locus in P. aer-
uginosa PAO1 and the pyocin S1 locus of P. aeruginosa 
ATCC 25324 suggests that the pyocin S6 gene has been 
present in the genome of these strains but got later largely 
deleted, leaving only the immunity gene intact. In addi-
tion to this rRNase- type of immunity gene, a putative 
tRNase immunity gene is present downstream of the pyocin 
S1 and S2 loci. Such orphan immunity genes could confer 
a competitive advantage to the bacterium as they may 
enable to neutralize a broader spectrum of invading  pyocins 
as was shown here for the orphan rRNase immunity gene 
of strain PAO1. Possibly, the pyocin S2 gene was later 
acquired by horizontal gene transfer. In line with this, 
an ORF remnant specifying part of a Tn3 transposon 
family protein was detected in the PAO1 pyocin S2 locus 
(Denayer et al. 2007).
The similarities in tertiary structures, together with the 
53% identity of the KDs and the conservation of catalytic 
residues, suggest that in target cells, pyocin S6 uses a 
killing action comparable to colicin E3 by inactivation of 
the host’s protein biosynthetic machinery through cleavage 
Figure 4. Determination of pyocin S6 activity and MIC (minimum inhibitory concentration). Of the 110 tested strains, 22 were found to be sensitive 
to the purified protein. Clear zones of inhibition only appeared when grown on casamino acids rather than on LB medium, as demonstrated here for 
the strain PA109 in figures B and A, respectively. (C) The MIC was determined for CF_PA109 by a twofold serial dilution; number 1 represents the 
undiluted purified fraction (17 mg mL−1). As dilutions increase, the killing zones become smaller and then become gradually more opaque due to 
incomplete inhibition.
(A)
(C)
(B )
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of a single ribonucleotide bond at the ribosomal A- site 
of 16S rRNA. This mode of action likely results in a 
bacteriostatic effect rather than a bactericidal activity as 
for example mediated by the DNAse killing domain of 
S2.
The fact that pyocin S6 shares similarity with colicins 
is not so surprising, since the same has been found for 
pyocins S1, S2, and AP41, where the DNase domains and 
the immunity proteins of these pyocins were found to 
be homologous to the corresponding regions of E2 group 
colicins; E2, E7, E8, and E9 (Sano et al. 1993). This dem-
onstrates that, over the course of evolution, pyocins have 
been subjected to forms of recombination and domain 
shuffling events with colicins and possibly bacteriocins of 
other bacteria. A conceivable explanation for this phe-
nomenon can be found in the clear structural organization 
that both bacteriocins have in common, even though the 
putative domains of pyocin S6 (RBD, TD, and KD) are 
differently arranged compared to those in colicin E3, in 
which the order is TD- RBD- KD from amino- to carboxy- 
terminal end. Similarly to other S- type pyocins, pyocin 
S6 could possibly targets sensitive cells by binding to an 
iron- regulated outer membrane receptor. Attempts to 
identify the receptor recognized by the RBD using the 
same strategy as for the identification of the FptA recep-
tor for pyocin S5 (Elfarash et al. 2014) did not succeed. 
In the case of pyocin S5, a combined library of transposon 
mutants of an S5- sensitive strain was subjected to the 
action of S5 and resistant colonies were found growing 
in the pyocin inhibition zone. This failure is probably 
due to the bacteriostatic activity of pyocin S6, which  allows 
regrowth of cells in the inhibition zone after a longer 
incubation period, hence masking the presence of true 
resistant clones after transposon mutagenesis.
Interestingly, the expression levels of the immunity gene 
are considerably higher than those of the pyocin S6 gene 
under both growth conditions used in this study. This 
seems contradictory to the operon- like genomic organiza-
tion of the genes. However, it has been shown that the 
expression of genes in an operon can be discoordinately 
regulated by means of small noncoding RNAs (sRNAs) 
(Balasubramanian and Vanderpool 2013). In the case of 
pyocin S6, such a discoordinate regulatory mechanism 
might protect the bacterial cell from spending energy in 
the production of the pyocin molecule, while under iron- 
limiting conditions, when the target receptors are abun-
dantly expressed, a different regulatory mechanism may 
stabilize the pyocin transcript. On the other hand, high 
basal expression of the immunity gene protects the pyocin- 
producing cell against invading pyocins, and in addition, 
ensures that it can rapidly respond to changing conditions. 
In a recent study, Gomez- Lozano et al. (2014) identified 
by RNA- seq analysis, 232 antisense RNAs in P. aeruginosa 
PAO1, one in the pyocin S5 gene, and three of them 
internal of the pyocin S4 coding sequence.
In our PCR- based screening of 110 CF strains of 
P.  aeruginosa, we found that 51% of the panel contains 
the pyocin S6 gene. It should be mentioned that in this 
collection of P. aeruginosa CF strains, there is a bias to-
ward strains belonging to the P. aeruginosa CF_PA39 clone 
(20 out of the 110 tested isolates), explaining the high 
frequency of isolates harboring the pyocin S6 gene and 
consequently the lower number of sensitive isolates, as 
compared to susceptibility frequencies for other pyocins. 
However, when screening the Pseudomonas Genome 
Database (Winsor et al. 2011) via BlastN, the complete 
pyocin S6 gene could not be retrieved from any of the 
available complete P. aeruginosa genomes, and was found 
in only six strains out the 996 complete and draft genomes 
(Table S1), including CF_PA39, two strains from respira-
tory infections, one abdominal infection isolate, one blood 
isolate, one urinary tract infection (UTI) isolate, and one 
tomato plant isolate.
Conclusion
This study has provided the first experimental evidence 
of a locus encoding a novel P. aeruginosa pyocin, termed 
pyocin S6, and its cognate immunity domain in the  genome 
of a cystic fibrosis isolate. The genes for this particular 
pyocin and its immunity protein are found in only few 
other clinical isolates, and even one nonclinical isolate, 
but are prominent in the strains belonging to the same 
CF clonal complex from the UZ Brussels. Sharing two 
domains with pyocin S1 (RBD and TD), its toxic activity 
is quite similar to that of colicin E3, a bacteriocin from 
E. coli that kills through site- specific cleavage of a single 
phosphodiester bond of 16S ribosomal RNA in the 30S 
subunit. In other Pseudomonas species, mainly isolated 
from plant and soil environments, putative bacteriocins 
with a colicin E3/pyocin S6- type of carboxy- terminal 
 domain occur frequently (Ghequire and De Mot, 2014). 
These molecules illustrate the significance of domain 
 shuffling in molecular evolution.
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